Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Vedanta Resources’ $500 mn dollar bonds attract 3x subscription
1er/10/2025
Vedanta Group's Sterlite Electric files DRHP with Sebi for an IPO
1er/10/2025
HUDCO, PFC, and Ireda shares jump up to 5% as RBI eases infrastructure financing norms
1er/10/2025
Netweb Technologies shares surge 13% to record high, rally 170% in 6 months ! Here’s why
1er/10/2025
Anand Rathi Share and Stock Brokers shares rally 13% from IPO price in 2 days as investor demand stays strong
1er/10/2025
Sunny Agrawal flags overpriced unlisted stocks amid IPO frenzy
1er/10/2025
